Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Inclusion Criteria: * Diagnosis of HD with documented CAG repeat ≥ 37 * UHDRS total maximal chorea score of ≥ 8 * Able to walk at least 10 meters * Medically stable outpatient, based on the investigator's judgment * Willing and able to give written informed consent prior to performing any study procedures * Have completed at least 10th grade * Montreal Cognitive Assessment score ≥ 22 on screening * Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion Exclusion Criteria: * Severe depression or suicidal ideation * History of suicidal behavior * Unstable or serious medical or psychiatric illness * Renal or hepatic impairment * Severe speech impairment or anarthria * Inability to swallow study medication * Women who are pregnant or breast feeding * History of alcohol or substance abuse within the last 12 months * Current use of VMAT2 inhibitor (tetrabenazine, deutetrabenazine, valbenazine) * Concurrent participation in any other investigational drug trials * EKG QTcF\> 500 mse